Background:

MEGF9 (Multiple EGF‑like domains protein 9; also EGF‑like protein 5) is a 63 kDa (predicted) novel transmembrane glycoprotein that shares some homology to beta ‑chains of laminin. It is expressed by hepatocytes, cerebellar Purkinje cells, Schwann cells, keratinocytes and intestinal epithelium. MEGF9 is suggested to participate in cell motility, and its absence correlates with tumor cell migration. Mature human MEGF9 is 572 amino acids (aa) in length. It is a single span type I transmembrane protein that contains a 484 aa extracellular region (aa 31‑514) plus a 68 aa C‑terminal cytoplasmic domain. The extracellular region possesses a lengthy Pro‑rich region (aa 55‑200), followed by five EGF‑like domains (aa 204‑451). MEGF9 may run at approximately 160 kDa in SDS‑PAGE, suggesting either heavy glycosylation or dimerization. Over aa 36‑514, human MEGF9 shares 76% aa sequence identity with mouse MEGF9.

Classification:

Primary antibody

Alternative names:

MEGF9; EGFL5; KIAA0818; Multiple epidermal growth factor-like domains protein 9; Multiple EGF-like domains protein 9; Epidermal growth factor-like protein 5; EGF-like protein 5

Species reactivity:

Human;Mouse;Rat

Host:

Rabbit

Isotype:

IgG

Immunogen:

The antiserum was produced against synthesized peptide derived from human MEGF9. AA range:383-432

Concentration:

1 mg/ml

Molecular weight:

62984

Applications:

WB, ELISA

Storage:

-20°C for one year

More info:

Email: info@sobekbio.com

Orders:

Email: orders@sobekbio.com